Enrolling

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)

J2J-OX-JZLC -

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib works when compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Breast Cancer
What the trial is testing?
LY3484356, Exemestane, Fulvestrant, Imlunestrant, Abemaciclib, LY2835219
Could I receive a Placebo?
No
Enrollment Goal
860
Trial Dates
Oct 4, 2021 - Aug 2027
How long will I be in the trial?
Your participation could last up to 5 years depending on how you and your tumor respond.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have HR+ HER2- breast cancer
  • Participants must have cancer that is advanced or has spread to another part of the body
  • Participants must have already received a drug that blocks the production of estrogen
  • Participants must have adequate body organ function
  • Participants must be in fair to good health
  • Participants must be able to swallow capsules/tablets

Participants Must Not:

  • Participants must not have received chemotherapy or some targeted therapies for advanced breast cancer
  • Participants must not have cancer that has spread to the brain that has not been treated or is causing symptoms
  • Participants must not have another serious medical condition

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources